Seres Therapeutics Inc (MCRB)

Apr 17, 2025

Down -48.7% in 4 Weeks, Here's Why Seres Therapeutics (MCRB) Looks Ripe for a Turnaround - NewsBreak: Local News & Alerts

Apr 17, 2025

Apr 16, 2025

MCRB stock touches 52-week low at $0.46 amid market challenges By Investing.com - Investing.com South Africa

Apr 16, 2025

Apr 16, 2025

MCRB stock touches 52-week low at $0.46 amid market challenges - Investing.com

Apr 16, 2025

Apr 14, 2025

Seres Therapeutics enacts stock incentive plan and reverse split By Investing.com - Investing.com South Africa

Apr 14, 2025

Apr 14, 2025

12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga

Apr 14, 2025

Apr 14, 2025

Seres Therapeutics enacts stock incentive plan and reverse split - Investing.com

Apr 14, 2025

Apr 12, 2025

Seres Therapeutics (NASDAQ:MCRB) Rating Lowered to Sell at StockNews.com - Defense World

Apr 12, 2025

Apr 11, 2025

Seres Therapeutics Inc (NASDAQ: MCRB): Blank Check On Growth? - stocksregister.com

Apr 11, 2025

Apr 11, 2025

Analysts Set Seres Therapeutics, Inc. (NASDAQ:MCRB) Price Target at $4.00 - Defense World

Apr 11, 2025

Apr 08, 2025

MCRB stock touches 52-week low at $0.54 amid market challenges - Investing.com Australia

Apr 08, 2025

Apr 08, 2025

MCRB stock touches 52-week low at $0.54 amid market challenges By Investing.com - Investing.com South Africa

Apr 08, 2025

Apr 03, 2025

INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Regarding Possible Violations of Federal Securities Laws by Certain Officers and Directors of Seres Therapeutics, Inc.MCRB - ACCESS Newswire

Apr 03, 2025

Apr 02, 2025

5 Best Microbiome Companies (April 2025) - Securities.io

Apr 02, 2025

Apr 01, 2025

Charles Schwab Investment Management Inc. Purchases 117,107 Shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) - Defense World

Apr 01, 2025

Mar 28, 2025

FY2025 Earnings Forecast for MCRB Issued By Chardan Capital - Defense World

Mar 28, 2025

Mar 28, 2025

Avantax Advisory Services Inc. Increases Stake in Seres Therapeutics, Inc. (NASDAQ:MCRB) - Defense World

Mar 28, 2025

Mar 23, 2025

Seres Therapeutics (NASDAQ:MCRB) Given "Buy" Rating at Chardan Capital - MarketBeat

Mar 23, 2025

Mar 22, 2025

Chardan Capital Reiterates Buy Rating for Seres Therapeutics (NASDAQ:MCRB) - Defense World

Mar 22, 2025

Mar 21, 2025

Microbiome Disease Pipeline Insight 2025: Over 180 Drugs in Development Across 140+ Companies - GlobeNewswire Inc.

Mar 21, 2025

Mar 20, 2025

Petri Dish: Flagship spinout Ampersand raises $65M, Seres medical chief lands new role - The Business Journals

Mar 20, 2025

Mar 17, 2025

Seres Therapeutics, Inc. (NASDAQ:MCRB) Receives $4.00 Consensus Target Price from Brokerages - Defense World

Mar 17, 2025

Mar 16, 2025

The Goldman Sachs Group Issues Pessimistic Forecast for Seres Therapeutics (NASDAQ:MCRB) Stock Price - Defense World

Mar 16, 2025

Mar 15, 2025

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Mar 15, 2025

Mar 14, 2025

Seres Therapeutics, Inc. (NASDAQ:MCRB) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 14, 2025

Mar 14, 2025

Seres Therapeutics, Inc. (NASDAQ:MCRB): Are Analysts Optimistic? - Yahoo Finance

Mar 14, 2025

Mar 14, 2025

Earnings call transcript: Seres Therapeutics Q4 2024 financial results disappoint By Investing.com - Investing.com South Africa

Mar 14, 2025

Mar 14, 2025

Seres Therapeutics Advances SER-155 Program with FDA Support - TipRanks

Mar 14, 2025

Mar 14, 2025

Seres Therapeutics Inc (MCRB) Q4 2024 Earnings Call Highlights: Financial Improvements and ... - Yahoo Finance

Mar 14, 2025

Mar 14, 2025

Seres Therapeutics (MCRB) Gets a Hold from Piper Sandler - The Globe and Mail

Mar 14, 2025

Mar 14, 2025

Seres Therapeutics Inc (MCRB) Q4 2024 Earnings Call Highlights: Financial Improvements and Strategic Developments - GuruFocus.com

Mar 14, 2025

Mar 13, 2025

Seres Therapeutics Earnings Call: Progress Amid Uncertainty - TipRanks

Mar 13, 2025

Mar 13, 2025

Seres Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 13, 2025

Mar 13, 2025

Evaluating MCRB’s financial ratios for a profitable investment - US Post News

Mar 13, 2025

Mar 13, 2025

Seres Therapeutics, Inc. SEC 10-K Report - TradingView

Mar 13, 2025

Mar 13, 2025

Earnings call transcript: Seres Therapeutics Q4 2024 financial results disappoint - Investing.com India

Mar 13, 2025

Mar 13, 2025

Seres Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates - The Manila Times

Mar 13, 2025

Mar 13, 2025

Seres Therapeutics Receives FDA Feedback Supporting SER-155 Study Plans for Bloodstream Infection Reduction in Allogeneic Hematopoietic Stem Cell Transplant Patients - Nasdaq

Mar 13, 2025

Mar 13, 2025

MCRBSeres Therapeutics Inc Latest Stock News & Market Updates - StockTitan

Mar 13, 2025

Mar 12, 2025

12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga

Mar 12, 2025

Mar 12, 2025

New Horizons in Microbiome Therapeutics Whitespace Analysis - openPR

Mar 12, 2025

Mar 11, 2025

Seres Therapeutics Inc expected to post a loss of 20 cents a shareEarnings Preview - TradingView

Mar 11, 2025

Mar 08, 2025

StockNews.com Upgrades Seres Therapeutics (NASDAQ:MCRB) to “Hold” - Defense World

Mar 08, 2025

Mar 07, 2025

Seres Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire

Mar 07, 2025

Mar 06, 2025

Seres Therapeutics (NASDAQ: MCRB) Stock Gains Momentum Ahead of Q4 Earnings - DRP Journal

Mar 06, 2025

Mar 06, 2025

Seres Therapeutics (MCRB) Expected to Announce Earnings on Thursday - Defense World

Mar 06, 2025

Mar 05, 2025

Live Biotherapeutics Market: Rapid Growth Fueled by Microbiome Innovations to Surpass $422.9 Million by 203... - WhaTech

Mar 05, 2025

Mar 04, 2025

Seres Therapeutics to Announce Fourth Quarter and Full Year - GlobeNewswire

Mar 04, 2025